Suggestions
Daniel Chen, M.D. Ph.D.
Physician-Scientist, Cancer Immunotherapy
Daniel S. Chen, M.D., Ph.D. is a prominent figure in the field of cancer immunotherapy and biotechnology. He is currently a Partner at Genesis BioCapital and has recently launched KOMO BIOSCIENCES, the first Genesis BioCapital company and technology.34
Professional Background
Dr. Chen has an extensive career in oncology and immunotherapy:
- He served as the Chief Medical Officer at IGM Biosciences, Inc.12
- Prior to that, he held the position of Vice President and Global Head of Cancer Immunotherapy Development at Genentech/Roche.12
- At Genentech/Roche, he played a crucial role in building the company's cancer immunotherapy segment and led the development of the anti-PD-L1 antibody drug Tecentriq®.2
Education and Early Career
Dr. Chen's educational background is impressive:
- He received a bachelor's degree in biology from the Massachusetts Institute of Technology (1990).1
- He earned both his Ph.D. in microbiology and immunology (1996) and M.D. (1998) from the University of Southern California.1
- He completed his internal medicine residency and Medical Oncology Fellowship at Stanford University (2003).1
- He also conducted a post-doctoral fellowship in immunology at Stanford.1
Research and Contributions
Dr. Chen has made significant contributions to the field of cancer immunotherapy:
- He ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003-2006.1
- He studied human anti-cancer immune responses and worked on developing better immunologic tools to examine human immune responses.1
- He patented the MHC cellular microarray to detect and functionally characterize antigen-specific T cell states.1
Current Endeavors
As a Partner at Genesis BioCapital, Dr. Chen is actively involved in launching new biotechnology ventures:
- He recently announced the launch of KOMO BIOSCIENCES, which aims to deliver transformative advances in gene insertion technology.345
Dr. Chen's expertise in immunotherapy, oncology, and biotechnology makes him a valuable asset in the field of innovative medical research and development.
Highlights
Super excited and happy to launch KOMO BIOSCIENCES, the first Genesis BioCapital company and technology! Komo is set to deliver transformative advances in #gene modification- from the dish, accelerating biologic therapy development and manufacturing, to patients. It's exactly the type of broad #technology and #engineering that Genesis seeks to create, incubate and help grow into companies that benefit human health. Amazing to have Jesse B. Owens, Jennifer Manning, Omid Harandi, Jay Wohlgemuth MD, Ray Tabibiazar, +++ as partners and founders making this happen!
Endpoints News https://lnkd.in/gNCN4PK9
https://lnkd.in/gaFSNSE8
https://lnkd.in/grdRWsud
https://lnkd.in/g3a7pqYT
#cancer #immunotherapy #CART #CMC #manufacturing #celltherapy #biologictherapy #autoimmunity #infectiousdisease #pandemic #therapeutics
An amazing day @PEGS Boston 2024 including Jim Wells, Paul Carter and David Liu back to back.
